This was announced on Wednesday by the founder and director of the BioNTech laboratory, Ugur Sahin. “Self-confident” in the effectiveness of a vaccine developed in conjunction with the American group Pfizer against the Indian variant of Covid-19.
If a “Tests” still in development, “The Indian variant has mutations that we have already studied and against which our vaccine works, which gives us confidence,” Sahin explained at an online press conference.
The B.1.617 variant, better known as the Indian variant due to its first appearance in India, has been found in “at least 17 countries” including the UK, the United States, Belgium, Switzerland and even the United States. Italy, according to the World Health Organization (WHO).
“Bastion” what vaccination is against Covid-19 “I’ll hold out, I’m sure of it” – Sahin added.
BioNTech has already tested its vaccine with more than 30 variants, each time receiving at least one “Sufficient immune response” he added.
Authorized soon in China
The director of a German RNA messenger startup that has become a global pioneer in immunization has also announced that his vaccine, which has been used in the EU and the US since December last year, should soon receive approval from Chinese health authorities.
“There are a few more open questions that we are answering.” as well as “Very likely to get permission by July”– the scientist specified.
He also said that he advocated easing restrictions on the vaccinated, but “this should not happen too quickly, or we will create envy.”
When 50 to 60% of Europeans are vaccinated at the end of May or June, this flexibility, “Scientifically Based”
“Will reach a significant part of the population”, – asserted Mr. Sakhin.